Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > November 19, 2020
Daily News
November 19, 2020
- Lilly’s Galcanezumab Up for PAFSC Review for Migraine Prevention on Dec. 2
November 19, 2020
- MHLW Mulls Health Follow-Up on 10,000-Plus COVID-19 Vaccine Recipients
November 19, 2020
- MHLW Expects Use of Dry Ice-Fitted Cooling Boxes to Deliver Ultracold Chain-Required COVID-19 Shots: Official
November 19, 2020
- Gilead’s JAK Med Hits Shelves in Japan; Launch Being Prepped for Oral Semaglutide, Rakuten Photoimmunotherapy
November 19, 2020
- Chuikyo Healthcare, Payer Reps Still Divided Over Off-Year Re-Pricing Debate
November 19, 2020
- Kyowa Kirin/Sandoz’s Rituxan Biosimilar Expands Label
November 19, 2020
- Half of Patients Postpone or Cancel Regular Checkups amid COVID-19: Roche Survey
November 19, 2020
- EFPIA Japan Chief Frets Declining Priority for Japan Market since 2018 Pricing Overhaul
November 19, 2020
- Number of Patients Treated by Pediatricians Shows Sharp Rebound in October: Survey
November 19, 2020
- 20% of Osteoporosis Patients Reduce/Halt Clinic Visits Amid COVID-19 Pandemic: Survey
November 19, 2020
- Daiichi Sankyo, CureApp Link Up on Cancer Treatment Support App, Eye Clinical Study in FY2021
November 19, 2020
- Nichi-Iko Files Avastin Biosimilar in Japan
November 19, 2020
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…